Overexpression of the protein kinase CK2 increases the survival and resistance to chemotherapy of acute myeloid leukemia cells by PAVAN, LAURA
Università degli Studi di Padova
Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche
SCUOLA DI DOTTORATO DI RICERCA IN ONCOLOGIA E ONCOLOGIA CHIRURGICA
CICLO: XXV
“OVEREXPRESSION OF THE PROTEIN KINASE CK2 INCREASES THE SURVIVAL AND
RESISTANCE TO CHEMOTHERAPY OF ACUTE MYELOID LEUKEMIA CELLS”
Direttore della Scuola: Ch.ma Prof.ssa Paola Zanovello
Supervisore: Ch.mo Prof. Gianpietro Semenzato
Dottoranda : Dott.ssa Laura Pavan

INDEX
ABBREVIATIONS 1
ABSTRACT 3
RIASSUNTO 5
INTRODUCTION 7
Acute myeloid leukemia 7
Incidence 7
Classification 7
The FAB classification 7
The WHO classification 8
European leukemia network (ELN) classification 10
Prognostic factors 10
Patient-related factors 11
AML-related factors 11
Cytogenetics 11
Molecular genetics 12
TP53 mutations in acute myeloid leukemia 13
Protein kinase CK2 15
The JAK STAT pathway 16
METHODS 19
Primary AML blasts, AML cell lines and cultures 19
Western blot (WB) and antibodies 19
Cytokines and chemicals 20
CK2 activity in cell lysates 20
Evaluation of growth and apoptosis 20
Immunofluorescence and confocal microscopy 21
Transient transfection and luciferase assays 21
Quantitative RT-polymerase chain reaction 21
RNA interference (RNAi) 22
Drug Combination Studies 22
Patients 22
Statistical analysis 24
RESULTS 25
Expression levels and kinase activity of CK2 are increased in AML cells 25
Inhibition of CK2 activity causes AML cell apoptosis 27
CK2 inhibitors-induced apoptosis is p53-dependent 29
AML cells show increased sensitivity to doxorubicin and daunorubicin after CK2 inhibition 32
CK 2 silencing by RNA interference causes apoptosis and empowers daunorubicin-dependent
citotoxicity in AML cells 34
CK2 subcellular localization is modulated by doxorubicin in AML cells 36
The combination of CK2 inhibitors and daunorubicin induces apoptosis of AML cells with a
Synergic effect 37
CK2 modulates daunorubicin-induced activation of JAK-STAT pathway 39
CK2 α and β expression analysis of in primary AML cells 41
Prognostic significance of CK2 α and β       43
DISCUSSION 45
REFERENCES 49
ACKNOWLEGDMENTS 51
1ABBREVIATIONS
AML acute myeloid leukemia
CEBPA CCAAT/enhancer-binding protein alpha
CK2 casein kinase 2
DAUNO daunorubicin
DOX doxorubicin
DMSO dimethyl sulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
ELN European leukemia network
FAB French-American-british
FCS fetal calf serum
FITC fluorescein isothiocyanate
FLT3 Fms-like tirosinKinase 3
NPM1 nucleophosmin 1
PCR plymerase chain reactio
PARP poly(ADP-ribose) polymerase.
TNFα      tumor necrosis factor α  
WB Western Blot
WHO World Health Organization
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3ABSTRACT
Background: The critical role of protein kinase CK2 in the regulation of cellular apoptosis suggests its
may be involvement in tumor cell resistance to both conventional and unconventional therapies.
Aim of the study: To study the role of CK2 in acute myeloid leukemia (AML) cell survival and response
to chemotherapeutic agents.
Methods: Apoptotic pathways were evaluated by AnnexinV/Propidium Iodide staining, Western Blot
analysis of Caspase3 and Parp cleavage and Real Time PCR of antiapoptotic gene expression.
Results: CK2 α catalytic subunit expression level and activity were increased in AML cells as compared 
to normal CD34+ hematopoietic cells. CK2 inactivation with the synthetic chemical inhibitors K27, CX-
4945 or RNA interference induced AML cell apoptosis of p53 wild-type but not of p53-null cells,
suggesting that the apoptosis triggered by CK2 inhibition needs the presence of functional p53. Inhibition
of CK2 activity with K27 or CX-4945 was associated to an increased sensitivity of the cytotoxic effects
of doxorubicin and daunorubicin. Cells were also nucleofected with siRNA oligos directed against CK2 α 
catalytic, β regulatory or both subunits. Interestingly RNA interference of CK2 β reduced cell 
viability and enhanced apoptosis induced by daunorubicin, indicating a prominent role of this subunit in
the resistance to chemotherapy.
Based on our in-vitro results we have then examined the expression level of CK2 α and β in 32 newly 
diagnosed AML patients (excluding acute promyelocitic leukemia) from 2008 to 2011. Preliminary data
shows a higher expression of the CK2 α subunit in the two AML subgroups with the highest risk based on 
cytogenetic characteristics. These laters nowadays represent the strongest prognostic factor predicting
chemoresistance. Interestingly we did not find a correlation with expression of the regulatory subunit
CK2 β. 
Conclusions: These data highlight the relevance of CK2 in AML cell survival for the influence of this
kinase on the activation of anti-apoptotic pathways implicated in AML cell resistance to chemotherapy.
A study to establish wether the CK2 expression at diagnosis represents an independent prognostic factor
in the progression free survival and overall survival for these patients is needed.
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5RIASSUNTO
Numerose evidenze supportano un ruolo fondamentale della protein chinasi CK2 nella regolazione
dell’apoptosi e della proliferazione cellulare nell’ambito dei tumori solidi. Ad oggi, tuttavia, un possibile
ruolo di CK2 anche nella patogenesi della leucemia mieloide acuta (LMA) risulta ancora incerto. Nel
presente lavoro sperimentale abbiamo testato l’ipotesi che CK2 potesse avere un ruolo nel modulare la
resistenza all’apoptosi e quindi la sopravvivenza delle cellule di LMA sia in condizioni basali sia in
risposta ad agenti chemioterapici. Abbiamo dimostrato che i livelli di espressione ed attività di CK2 sono
aumentati nelle cellule di LMA rispetto alla controparte normale costituita dalle cellule staminali CD34+.
Studi di localizzazione intracellulare ci hanno consentito di osservare una concentrazione preferenziale di
CK2 a livello citoplasmatico. Abbiamo dimostrato che il blocco dell’attività chinasica determina un
aumento di espressione della proteina p53, la mancanza della quale rende le cellule di LMA resistenti
all’apoptosi indotta dagli inibitori di CK2. Ipotizzando un ruolo di CK2 nella chemioresistenza delle
cellule di LMA, abbiamo dimostrato che il blocco dell’attività di CK2 incrementa la sensibilità di tali
cellule al trattamento con chemioterapici quali doxorubicina e daunorubicina.
Sulla base dei risultati ottenuti in vitro abbiamo analizzato l’espressione di CK2 α e β in 32 pazienti con 
leucemia mieloide acuta di nuova diagnosi (ad esclusione della leucemia promielocitica) dal 2008 al 2012.
Risultati preliminari mostrano come CK2 α sia più elevata nei pazienti appartenenti a gruppi a piu’ alto 
rischio in base alla classificazione dell’ European Leukemia Network (ELN) e la sua aumentata
espressione, seppur non in modo statisticamante significativo, appaia correlata ad una peggior overall
survival nel gruppo omogeneo di pazienti sottoposto a chemoterapia. Per la subunità β al contrario non è 
risultata alcuna correlazione.
Possiamo concludere che CK2 interviene nella sopravvivenza delle cellule di LMA modulandone la
resistenza all’apoptosi in maniera p53 dipendente e l’aumentata espressione della subunità catalitica α alla 
diganosi puo’ rappresentare un nuovo fattore prognostico in questa patologia così eterogenea. Il suo ruolo
all’interno delle attuali classificazioni dovrà essere validato in futuro su un’ampia casisitica di pazienti.
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7INTRODUCTION
Acute myeloid leukemia
Leukemia is a heterogenous group of diseases characterized by clonal cells that exhibit maturation defects
that correspond to stages in hematopoietic differentiation. Hematopoietic stem cells are multipotent and
have the capacity to differentiate into the cells of all 10 blood lineages — erythrocytes, platelets,
neutrophils, eosinophils, basophils, monocytes, T and B lymphocytes, natural killer cells, and dendritic
cells. In order to sustain hematopoiesis, stem cells are part of a developmental hierarchy capable of three
basic functions:
Maintenance in a non-cycling state (ie, not actively progressing through the cell cycle)
Self-renewal, allowing production of additional stem cells
Production of committed progenitor cells
These progenitor cells commit to subsets of myeloid and lymphoid lineages, and ultimately to single
developmental pathways, resulting in the expression of the terminally differentiated stage of each cell
type
Acute myeloid leukemia (AML) develops as the consequence of a series of genetic changes in a
hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation,
resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow
and peripheral blood. These cells are capable of dividing and proliferating, but cannot differentiate into
mature hematopoietic cells.
Incidence
Acute myeloid leukemia represents the commonest acute leukemia in adults; 3 per 100.000 annually. The
frequency increases with the age (median 64; incidence 35/100.000 at age 90). 66% are > 60 years of age.
Classification
The FAB classification
In the 1970s, a group of French, American, and British leukemia experts divided acute myeloid
leukemias into subtypes, M0 through M7, based on the type of cell from which the leukemia developed
and how mature the cells are (1). This was based largely on the microscope analysis after routine staining.
8Subtypes M0 through M5 all start in precursors of white blood cells. M6 AML starts in very early forms
of red blood cells, while M7 AML starts in early forms of cells that make platelets.
The WHO classification
The current WHO classification (table 1) established in 2008 reflects the fact that an increasing number
of acute leukemias can be categorized based upon their underlying cytogenetic or molecular genetic
abnormalities, and that these genetic changes form clinico-pathologic-genetic entities (Table 2) (2,3).The
subgroup “AML with recurrent genetic abnormalities” comprises several primary AML entities. “AML
with t(8;21)(q22;q22); RUNX1-RUNX1T1” and “AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);
CBFB-MYH11” are considered as AML regardless of bone marrow blast counts. In “APL with
t(15;17)(q22;q12); PML-RARA,” RARA translocations with other partner genes are recognized separately.
The former category “AML with 11q23 (MLL) abnormalities” was redefined in that “AML with
t(9;11)(p22;q23); MLLT3-MLL” is now a unique entity; balanced translocations other than that involving
MLLT3 should be specified in the diagnosis. Three new cytogenetically defined entities were
incorporated: “AML with t(6;9)(p23;q34); DEK-NUP214”; “AML with inv(3)(q21q26.2) or
t(3;3)(q21;q26.2); RPN1-EVI1”; and “AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1,” a
rare leukemia most commonly occurring in infants. Two new provisional entities defined by the presence
of gene mutations were added, “AML with mutated NPM1 [nucleophosmin (nucleolar phosphoprotein
B23, numatrin)],” and “AML with mutated CEBPA [CCAAT/enhancer binding protein (C/EBP), alpha].”
There is growing evidence that these 2 gene mutations represent primary genetic lesions (so-called class
II mutations)(4) that impair hematopoietic differentiation. Mutations in the fms-related tyrosine kinase 3
(FLT3) gene are found in many AML subtypes and are considered class I mutations conferring a
proliferation and/or survival advantage. AML with FLT3 mutations are not considered a distinct entity,
although determining the presence of such mutations is recommended by WHO because they have
prognostic significance. The former subgroup termed “AML with multilineage dysplasia” is now
designated “AML with myelodysplasia-related changes.” Dysplasia in 50% or more of cells, in 2 or more
hematopoietic cell lineages, was the diagnostic criterion for the former subset. AMLs are now categorized
as “AML with myelodysplasia-related changes” if (1) they have a previous history of myelodysplastic
syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and evolve to AML with
9a marrow or blood blast count of 20% or more; (2) they have a myelodysplasia-related cytogenetic
abnormality or (3) if 50% or more of cells in 2 or more myeloid lineages are dysplastic. “Therapy-related
myeloid neoplasms” has remained a distinct entity; however, since most patients have received treatment
using both alkylating agents and drugs that target topoisomerase II for prior malignancy, a division
according to the type of previous therapy is often not feasible. Therefore, therapy-related myeloid
neoplasms are no longer subcategorized. Myeloid proliferations related to Down syndrome are now listed
as distinct entities.
Table 1: The WHO CLASSIFICATION 2008
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European leukemia network (ELN) classification
In 1990, 2003 and more recently in 2010 expert working groups published recommendations for
diagnosis, standardization of response criteria and treatment outcomes and reporting standards for clinical
trials in AML (24,25,23). These are widely adopted in general practice, within clinical trials and by
regulatory agencies. In 2010 the panel proposed a standardized reporting system for genetic abnormalities
presenting data correlating genetic findings with clinical outcome allowing for a better comparison of
data among studies (table 2). This standardized report includes data from cytogenetic analysis and from
mutation analysis of the NPM1, CEBPA and FLT3 genes.
Table 2: AML classification propsed by the European Leukemia network (ELN classification)
Prognostic factors
Prognostic factors may be subdivided into those related to patient characteristics and general health
condition and those related to characteristics particular to the AML clone. The former subset usually
predicts treatment-related mortality (TRM) and becomes more important as patient age increases while
the latter predicts resistance to, at least, conventional therapy.
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Patient-related factors
Increasing age is an adverse prognostic factor (5). Even after accounting for risk factors, such as
cytogenetics, molecular genetics, type of AML (ie, de novo AML; AML with previous history of MDS or
MDS/MPN; therapy-related AML), and performance status, older patients have worse outcomes than
younger patients, suggesting the effect of unknown age-related factors. Nonetheless, age is not the most
important prognostic factor for either TRM or resistance to therapy. Attention should be given to a careful
evaluation and documentation of comorbidities. In a recent study of patients older than 60 years of age
receiving induction therapy (idarubicin 12 mg/m2 for 3 days, cytarabine 1.5 g/m2 for 3 days), scoring of
baseline comorbidities using the hematopoietic cell transplantation comorbidity index (HCTCI) was
predictive of early death rates and overall survival (OS) (6).
AML-related factors
AML-related prognostic factors includes white blood count (WBC), existence of prior MDS, previous
cytotoxic therapy for another disorder and cytogenetic and molecular genetic changes in the leukemic
cells at diagnosis. Various other factors, such as splenomegaly and elevated serum lactate dehydrogenase
(LDH) levels, have been reported to confer some prognostic effect but with variable consistency among
studies. The significance of a prognostic factor is always dependent on the therapy given to a patient.
Cytogenetics
The karyotype of the leukemic cells is the strongest prognostic factor for response to induction therapy
and for survival (7,8). Younger adult patients are commonly categorized into 3 risk groups, favorable,
intermediate or adverse (9). The most appropriate risk group assignment for a number of the rarer
cytogenetic abnormalities, for example, del(7q), isolated trisomy 8, del(9q), t(v;11)(v;q23) other than
t(9;11), and del(20q), remains uncertain due to limitations of sample size and differences in treatment
schedule among studies. Complex karyotype, which occurs in 10% to 12% of patients, has consistently
been associated with a very poor outcome (10). Complex karyotype has been defined as the presence of 3
or more (in some studies ≥ 5) chromosome abnormalities in the absence of t(8;21), inv(16) or t(16;16), 
and t(15;17), because in most studies increased karyotype complexity in these subgroups did not
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adversely affect outcome. As indicated in the new WHO classification, cases with other recurring genetic
abnormalities, such as AML with t(9;11) or t(v;11), AML with inv(3) or t(3;3), and AML with t(6;9)
should also be excluded, because these groups constitute separate entities (3). Recently, a new cytogenetic
category has been proposed that distinguishes AML of particularly unfavorable risk, that is, the
monosomal karyotype (11). In this study, the monosomal karyotype was defined by the presence of one
single monosomy (excluding isolated loss of X or Y) in association with at least one additional
monosomy or structural chromosome abnormality (excluding core-binding factor [CBF] AML). One
striking observation is the increasing incidence of adverse versus favorable cytogenetic abnormalities
with increasing age. This, at least in part, contributes to the poorer outcome of AML in older adults (5,12).
Molecular genetics
Gene mutations and deregulated gene expression have been identified that allow us to decipher the
genetic diversity within defined cytogenetic groups, in particular the large and heterogeneous group of
patients with CN-AML (Fig.1) (13,14,15). Prognostic significance within CN-AML has consistently been
shown for mutations in the NPM1, CEBPA, and FLT3 genes alone or in combination in younger adult
patients. CN-AML patients harboring internal tandem duplication (ITD) of the FLT3 gene have an
inferior outcome compared with cases without FLT3-ITD (15,16,17). In several, but not all studies, the
presence of NPM1 mutation in CN-AML has been associated with higher CR rates and better RFS and
event-free survival (EFS) (18,19). Of note, approximately 40% of patients with NPM1 mutations also
carry FLT3-ITD, and multiple studies have shown that the genotype “mutated NPM1 without FLT3-ITD”
represents a favorable prognostic marker, with higher CR rates, and better RFS and OS that is reminiscent
of that seen in patients with inv(16) or t(8;21).(15,18-20). CN-AML with mutations in CEBPA is another
subset that has been associated with a favorable prognosis (15,21). The survival data are very similar to
those of AML patients with mutated NPM1 without FLT3-ITD. Two recent studies suggest that there is
heterogeneity among mutated CEBPA cases, in that only cases with double mutations, usually biallelic,
have a favorable outcome (22). It remains an open question whether the presence of a FLT3-ITD impacts
on prognosis in patients with mutant CEBPA (15). In cytogenetically favorable CBF AML [ie, AML with
t(8;21) or inv(16)/t(16;16)], the presence of a KIT mutation has been shown to have an unfavorable
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influence on outcome in retrospective studies. There is a growing list of genetic abnormalities that are
being investigated: these include mutation analyses of the WT1, RUNX1, TET2, and IDH1 genes, and the
analyses of gene expression signatures, or of deregulated expression of single genes, such as EVI1, ERG,
M N1, and BAALC genes (23).
Figure 1: Pie chart illustrating the molecular heterogeneity of cytogenetically normal AML based on mutations in the
NPM1, CEBPA, MLL, FLT3 (ITD and TKD mutations at codons D835 and I836), NRAS, and WT1 genes.
The bluish colors denote NPM1-mutated subsets, the orange/red colors CEBPA-mutated subsets, and the yellow/green colors
MLL-mutated subsets. The gray colors depict subsets without hypothetical class II mutations, and the white sector shows the
subset without any mutation in the above-mentioned genes. Data are derived from mutational analysis of 485 younger adult
patients with cytogenetically normal AML from AMLSG.
TP53 mutations in acute myeloid leukemia
In AML TP53 alterations (mutations and/or losses) have been closely associated with AML with complex
karyotype (CK-AML), occurring in approximately two-thirds of the cases. Clinically TP53 alterations
appear to be associated with inferior outcome. In a recent analysis of 234 AML patients, cases with TP53-
altered were characterized by a higher degree of genomic complexity TP53-altered more frequent
exhibited a monosomal cariotype. Patients with TP53 alterations were older and had a significantly lower
complete remission rates, inferior event-free and overall survival (26).
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Protein kinase CK2
Protein kinase CK2 is a ubiquitous serine-threonine kinase involved in a multitude of cellular processes.
CK2 is a tetramer enzyme composed most often by two catalytic subunits (α or α’, encoded by separate 
genes) and two molecules of the regulatory subunit (β), so that the possible species in the cells are α 2 β 2
or α α’ β 2 (27). CK2 phosphorylates a great number of substrates with disparate functions (28). Deletion
of CK2 α and β in mice is embryonic lethal (29) and knock out of CK2 α’ results in globozoospermia and 
other defects (30).
A remarkable feature of CK2 is the frequent overexpression and high kinase activity displayed in several
types of malignant solid tumors. Indeed, CK2 has been demonstrated to contribute to the malignant
phenotype and tumor progression in mouse models as well as in human cancer cells (31). In this regard, a
peculiar property of CK2 is the ability to protect cells from apoptosis (32). This action is believed to be
achieved through several mechanisms. For instance, CK2 interferes with tumor suppressor Promyelocytic
leukemia (PML) and PTEN protein stability and function by phosphorylating critical serine residues on
these proteins and rendering them less active: in the case of PML through enhanced proteasome-mediated
degradation, in the case of PTEN through the stabilization of a less active form of the molecule (33,34).
CK2 phosphorylation of anti-apoptotic molecules also contributes to protection from apoptosis. CK2
targets Apoptosis Repressor with Caspase Recruiting domain (ARC), shifting the molecule to the
mitochondria where it inhibits caspase 8 (35). In addition CK2 phosphorylation of BID protects it from
caspase 8 cleavage and cell death (36) and positively regulates growth-promoting cascades, such as the
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PI3K/AKT (37), the NF-kB and the Wnt/β-catenin signaling pathways with the result of strongly 
directing cell fate towards survival and against programmed cell death (38).
Interestingly, a recently proposed unifying model for CK2 function relies on the regulation of the
Cdc37/Hsp90 chaperone complex through S13 phosphorylation on Cdc37 (39). This modification is
essential for the chaperoning activity of Hsp90 directed towards an array of client protein kinases, many
of which are oncogenic. CK2 has also been involved in the cellular DNA damage response, since it was
shown that this kinase can regulate both single strand and double strand DNA break repair, by facilitating
the XRCC1 function (40) and the UV light response by activating the NF-kB pathway and
phosphorylating the high mobility group protein SSRP1 (41,42).
Taken together, the established role played by CK2 in tumorigenesis, could rely on the extraordinary
property of this kinase to “addict” cells towards an apoptosis-resistant, proliferation and DNA damage
repair-prone-phenotype (42). Whereas CK2 expression and activity of in a number of solid tumors are
more defined, its function in blood cancers is less understood.
The JAK STAT pathway
The JAK-STAT pathway is crucial in transmitting signals from many cytokines and growth factors into
the nucleus, regulating gene expression. Cytokines of the IL-6 family, type I and II IFNs, and growth
factors such as growth hormone (GH) activate the JAK-STAT signaling pathway. Oncostatin M (OSM), a
cytokine belonging to the IL-6 family, is a potent activator of the JAK-STAT signaling pathway (43).
Binding of OSM induces heterodimerization of its receptors, gp130 and OSMRβ, and the receptor-
associated JAKs, JAK1 and JAK2, become activated, leading to phosphorylation of gp130 tyrosine
residues. The phosphorylated residues direct the recruitment of STAT proteins, including STAT-3,
STAT-1, and STAT-5, which in turn become JAK substrates. Activated tyrosine–phosphorylated STATs
form homodimers or heterodimers, translocate to the nucleus, and bind to consensus sequences in the
promoters of OSM-responsive genes, inducing transcription (44). The JAK tyrosine kinase family
comprises 4 mammalian members: JAK1, JAK2, JAK3, and TYK2. JAK2 is essential in erythropoiesis
(45), and its dysfunction has been implicated in myeloproliferative disorders (MPDs) and leukemias (46).
Both CK2 and JAK-STAT signaling play pivotal roles in cell survival, proliferation, and antiapoptotic
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mechanisms, and their dysregulation is associated with human malignancies. However, little is known of
potential cross-talk between CK2 and the JAK-STAT pathway. Recently Zheng et al demonstrated in
primary or immortalized mouse embryonic fibroblasts (MEFs) that silencing of CK2α or CK2β 
expression led to reduced OSM-induced STAT-3 activation. The inhibitory effect was most pronounced
when both CK2α and CK2β were diminished in expression. The same effect was shown using CK2 
chemical inhibitors such as TBB, whereas the inhibitory effect of TBB on STAT-3 activation was
abolished by introducing HA-CK2α-inhibitor resistant concluding that CK2 expression and activity is 
required for OSM-induced STAT-3 tyrosine phosphorylation (47).
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METHODS
Primary AML blasts, AML cell lines and cultures
Patients were charged to the University of Padova Hospital. Informed consent was obtained from patients
according to the declaration of Helsinki. AML blasts from peripheral blood (PB) and bone marrow (BM)
were obtained from PB and BM aspirates of patients and processed as described (48). Acute myeloid
leukemia NB4 (acute promyelocytic leukemia, FAB M3), HL60 (acute myeloblastic leukemia, FAB M2),
ML2 (acute myelo-monocytic leukemia, FAB M4), K562 (Philadelphia-positive chronic myeloid
leukemia in blast crisis), human osteosarcoma Saos-2 and human embryo kidney HEK293 and human
bone marrow HS-5 cell lines were purchased from the German Collection of Microorganisms and Cell
Cultures (DSMZ) and the American Type Culture Collection (Rockville, USA). Normal CD34+
haematopoietic stem cells (HSC) were obtained from PB or BM healthy donors. In co-culture
experiments, AML blasts from patients were seeded on top of a monolayer of HS-5 stromal cells. After
the indicated time points and treatments, AML blasts were gently removed from the HS-5 cells by
washing with PBS and subsequently processed for downstream analysis. Cell lines were maintained in
RPMI 1640 or DMEM medium, both supplemented with 10% fetal bovine serum, L-glutamine,
antibiotics (Gibco Laboratories, Grand Island, NY, USA) under controlled-atmosphere in incubators at
37 °C in the presence of 5% CO2.
Western blot (WB) and antibodies
Whole cell extracts were prepared by lysis with 20 mM Tris, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA,
0.5% Triton X-100 supplemented with complete protease inhibitor cocktail (Complete Mini; Roche,
Basel, Switzerland), 1 mM dithiothreitol (DTT; Amersham Biosciences, Little Chalfont,
Buckinghamshire, United Kingdom), 1 mM phenyl-methyl-sulfonyl fluoride (PMSF; Sigma-Aldrich), 10
μM sodium fluoride (Sigma-Aldrich), 1 μM okadaic acid, and 1 mM sodium orthovanadate (Calbiochem, 
San Diego, CA). 40 to 60 µg of whole cell extracts (WCE) or nuclear and cytoplasmic sub-fractions were
subjected to SDS-PAGE and processed by immuno-blot. Detection was performed using
chemiluminescence reaction (Pierce, USA). Proteins were subjected to SDS-PAGE, transferred to
nitrocellulose membranes, and immunoblotted with the following primary antibodies: anti-CK2 α-subunit 
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rabbit antiserum raised against the [376-391] region of human protein38; anti-CK2β (BD Bioscences, 
USA); anti-PARP and anti-SMAC/DIABLO, anti-STAT3, phospho-Tyr702-STAT3, and phospho-
Ser727-STAT3 (Cell Signaling, Beverly, MA); anti-caspase-3, anti-caspase-9, and anti-caspase-8
(Calbiochem-Merck Biosciences, Bad Soden, Germany); anti-SOCS3 (Cell Signaling Technology,
Beverly, MA, USA) and anti-p65 (CT) (Upstate Biotechnology, Lake Placid, NY). As protein
normalization:GAPDH (Ambnon) and β-actina (Sigma-Aldrich, Germania) were used. 
Detection was performed by ECL chemiluminescence reaction according to the manufacturer's
instructions (Amersham Biosciences). When indicated, densitometry was performed with ImageJ 1.34 S
software (Apple, Cupertino, CA).
Cytokines and chemicals
- Daunorubicin, Doxorubicin and MG132 were respectively purchased from Pfizer and Sigma-
Aldrich, Italy.
- CK2 inhibitors: K27 purchased from Dott. Z. Kazimierczuk (Warsaw, Poland) and CX-4945
(Activate Scientific GmbH).
CK2 activity in cell lysates
CK2 activity was determined as previously described (48). The CK2 activity was in a linear range
according to the lysate protein amount used for the assay.
Evaluation of growth and apoptosis
AML cell growth was monitored using the MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium
bromide)-based assay, according to the manufacturer’s protocol (Roche, Monza, Italy) and as described
elsewhere (48). Apoptosis was assessed by Annexin V/Propidium Iodide staining (BD Pharmingen) as
per manufacturer’s instructions using a FACScalibur cytofluorometer with the CellQuest® analytic
software (Becton Dickinson).
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Immunofluorescence and confocal microscopy
Preparation of cell samples was done as described (48). For confocal imaging, a Nikon Eclipse TE300
inverted microscope equipped with a PerkinElmer Ultraview LCI confocal system was employed;
excitation was performed using the appropriate laser lines. Magnification was set at 600x, using an oil
immersion objective. Antibodies used were: ant-CK2 described above, Alexa Fluor® 594 goat anti-
rabbit (Molecular Probes Europe, The Netherlands).
Transient transfection and luciferase assays
For luciferase assay experiments, HEK293 cell lines at 3 x 105 cells/well were transfected with an NF-B
luciferase reporter plasmid (Stratagene, La Jolla, CA) using the FuGENE transfection reagent (Roche
Diagnostics, Almere, The Netherlands) according to the manufacturer’s instructions and as described
elsewhere (48). The Dual Luciferase Reporter System (Promega, Madison, WI) was used according to the
supplier’s protocol. Experiments were performed in triplicate or quadruplicate. In p53 overexpression
experiments p53 null Saos-2 cells were transfected with the empty pCMV or pCMV-p53WT vectors
(kind gift of Dr. P.P. Pandolfi, Harvard University, MA, USA) using the Lipofectamine reagent (Life
Technologies, Carlsbad, CA, USA) according to manufacturer’s instructions.
Quantitative RT-polymerase chain reaction
Total RNA was extracted using the RNAeasy Mini Kit Protocol (Qiagen, Hamburg, Germany) and
complementary-DNA was synthesized using the Reverse Trascription System (Promega Corporation,
Madison, WI, USA), according to the manufacturers’ instructions. Real time PCR reactions were carried
out on an ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA). Reactions
were performed with SYBR Green PCR Master Mix (Invitrogen Corporation, Carlsbad, CA, USA). -
actin was used as reference gene for the adjustment of relative expression data. All assays were performed
at least twice to ensure their reproducibility, and a negative control was included in each run.
Oligonucleotides used are the following: -actin Forward 5’-CCAGCTCACCATGGATGATG-3’ and
22
Reverse 5’-ATGCCGGAGCCGTTGTC-3’, CK2 Forward 5’-TCTGAAGGCCCTGGATTATTGT-3’
and Reverse 5’-TCGAGAGTGTCTGCCCAAGATAT-3’.
RNA interference (RNAi)
For RNA interference the electroporator Nucleofector (Amaxa Biosystems) and the kit (Lonza,
Switzerland) for electroporation was used. For transfection of specific-CK2α smart pool interfering RNA 
(siRNA: GCAUUUAGGUGGAGACUUC; GGAAGUGUGUCUUAGUUAC;
GCUGGUCGCUUACAUCACU; AACAUUGUCUGUACAGGUU) and of CK2β (siRNA: 
CAACCAGAGUGACCUGAUU; GCAAGGAGACUUUGGUUAC; GCAAUGAAUUCUUCUGUCA;
CCAAGUGCAUGGAUGUGUA) were purchased from Thermo Scientific. The cell suspension (2 × 106
leukemia cells) was immediately electroporated by according to the manufacturer's instructions.
Immediately after electroporation, the cells were suspended in the complete medium and incubated in a
humidified 37°C/5% CO2 incubator. The cells were harvested after variable times and used for the
experiments.
Drug Combination Studies
To study the effect of the use of chemotherapeutic agents and CK2 inhibitors the combination index (CI)
theorem of Chou Talalay that offers quantitative definition for additive effect (CI=1), synergism (CI < 1)
and antagonism (CI > 1) in drug combinations was applied (49). This method also provides algorithms for
automated computer simulation for synergism and/or antagonism at any effect and dose level.
To assess cell growth the method of tritiated thymidine was used.
Patients
A total of 32 primary untreated AML patients were included in this study. The diagnosis was made in our
Unit between January 2008 and July 2012. Pretreatment cytogenetic analysis of bone marrow was done in
all patients considering at least 25 metaphases. The analysis of NPM1 and FLT3 was performed in 23
patients (Dott.sse Bonaldi e Bertorelle, Istituto Oncologico Veneto). The expression of CK2 α and CK2 β 
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in the bone marrow or in the peripheral blood was analysed at diagnosis as above described. AML
samples selected for expression profile studies presented a blasts percentage of at least 80%. All patients
were evaluated for CK2 β expression, 27 patients for CK2 α.  The caracteristics of patients are described 
in the table 3:
Table 3: Patients’ characteristics
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Statistical analysis
Data obtained were evaluated for their statistical significance with the two-tail paired Student’s t test.
Values were considered statistically significant at p values below 0.05. Patients were divided into two
groups (CK2α-high versus CK2α-low) according to the levels of constitutive expression of CK2α protein 
in pretreatment AML samples. The CK2α-high cases were arbitrary defined as cases showing the ratio of 
(CK2 absorbance/GAPDH absorbance) > 0,75. The same arbitrary cut off was adopted for the  subunit.
The overall survival probability was calculated using the Kaplan-Meier method. Log-rank statistics were
used to test the difference in survival times between groups.
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RESULTS
Expression levels and kinase activity of CK2 are increased in AML cells
Since CK2 is critically involved in cell survival and its protein levels have been found increased in an
array of solid tumor cells, we asked whether a common hematologic malignancy, like AML, could also
present alterations in CK2 protein levels and activity. We first analyzed CK2 and CK2 expression in
different AML cell lines, including K562, NB4, HL60 and ML2. Western blot (WB) analysis was
performed on total protein lysates using a rabbit polyclonal antibody recognizing the CK2 C-terminal
region, previously characterized (50). As control, CD34+ healthy hematopoietic stem cells were used. All
AML cell lines analyzed showed significantly higher levels of CK2 protein as compared to CD34+
control cells. Among the different AML cell lines, the K562 displayed the highest CK2 levels (up to
fourteen-fold more as compared to CD34+ cells); NB4 and ML2 showed intermediate (up to seven-fold
more as compared to CD34+ cells) and HL60 cells the lowest CK2 levels (Fig. 1A). We next looked at
whether CK2 mRNA levels paralleled the trend of the protein levels. Indeed, CK2 mRNA expression,
as evaluated by qRT-PCR, displayed a trend fairly reproducing that showed by the protein (Fig. 1B).
We then analyzed CK2 subcellular localization in AML cells. To this aim confocal microscopy
immunofluorescence experiments were performed using the ML2 AML cell line. CK2was detectable
mostly in the cytoplasm of AML cells, in which high fluorescence intensity was observed (Fig.1C).
To test whether cellular levels of CK2 paralleled its kinase activity, we measured CK2-directed kinase
activity using a radioactive kinase assay against a specific synthetic peptide, in AML and control cells
(Fig. 1D). Rather surprisingly, however, we could not detect a correlation between the observed
CK2protein levels and its kinase activity. In fact, when normalized against the total CK2 protein
levels (Fig. 1E), our data showed that cells with the highest CK2 protein levels, namely K562, displayed a
CK2-specific kinase activity comparable with that of control CD34+ cells, whereas significantly higher
CK2-specific kinase activity was detected in protein extracts from NB4 and ML2 cells (p<0.01, n=3
experiments). HL60 cells showed intermediate to low kinase activity levels.
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Figure 1: Expression of CK2 in cell lines of acute myeloid leukemia
A. Densitometric values of CK2α expression obtained by Western blot of total protein lysates belonging to the cell lines K562, 
HL60, NB4 and ML2. The control is represented by CD34 + stem cells
A B
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B. Expression of CK2α determined by real-time PCR performed on cDNA cell lines K562, HL60, NB4 and ML2. The control is 
represented by stem cells CD34 + (p <0.05)
C. Location of CK2: Immunofluorescence conducted on cells ML2 using an antibody directed against CK2α (red). Nuclei were 
marked with DAPI (blue).
D. CK2α activity determined by radioactive kinase assay of total cell lysates (K562, HL60, NB4, ML2). The normal control is 
represented by CD34 + stem cells. The results are representative of 3 separate experiments p <0.01.
E. Relationship between the kinase activity of CK2α and its protein expression levels (arbitrary units) in the various cell lines of 
acute myeloid leukemia (K562, HL60, NB4, ML2) and normal CD34 + hematopoietic stem cells. The results are
representative of 3 separate experiments p <0.01
Inhibition of CK2 activity causes AML cell apoptosis
To investigate the CK2 role in AML cell survival, different AML cell lines were treated with the CK2
inhibitors, K27 and CX-4945. After eighteen-hours exposure of ML2, HL60 and NB4 cells to increasing
concentration of the inhibitor, cell survival was analyzed by annexin V/propidium iodide (AV/PI) staining
and FACS analysis. AML cells were treated with the vehicle (DMSO 0.1% in medium), as a control.
Each cell line displayed a different sensitivity to CK2 inhibition. ML2 and NB4 cells resulted extremely
sensitive to CK2 inhibitors, while HL60 cells showed a remarkable resistance to the treatment, being
refractory to inhibitors used K27 (Fig. 2A) and CX-4945 (Fig 2B) at all the concentrations tested.
Moreover, immunoblot analysis of PARP cleavage also revealed that the treatment of AML cells with
CK2 inhibitors was able to trigger the apoptotic pathways, in a dose-dependent fashion, in ML2, NB4, but
not in HL60 cells (Fig. 2C and 2D).
To confirm that inhibition of CK2 results also in apoptosis of primary AML blast from patients, we
treated with 5M K27 freshly isolated AML blasts from 4 different patients and analyzed AV staining by
flow cytometry after 8 hours. CK2 inhibition indeed caused a statistically significant induction of
apoptosis (AV positive cells) also of primary AML cells, supporting the results obtained with the AML
cell lines (p<0.01, n=4) (Fig. 3).
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Figure 2: Response of apoptotic cells of acute myeloid leukemia after inhibition of CK2A with K27 and CX-4945.
A. In different cell lines of acute myeloid leukemia (ML2, NB4 and HL60) CK2 was inhibited by treatment with K27 at
increasing concentrations (0.5-1.5-5-10-20μM) for 18 hours. The extent of apoptosis was assessed by annexin V test. The 
abscissa shows the different concentrations of K27 used, on the ordinate the percentage of cells positive for annexin V
(apoptotic). The results shown are representative of 3 separate experiments (p <0.05).
B. The expression of total and cleaved PARP was determined by Western-blot analysis of protein lysates of NB4 cells, ML2 and
HL60 following treatment for 18 hours with increasing doses of K27 and respective normalization with β-actin  
C. In different cell lines of acute myeloid leukemia (ML2, NB4 and HL60) CK2 was inhibited by treatment with CX-4945 at
increasing concentrations (5-10-15 μM) for 18 hours. The extent of apoptosis was assessed by annexin V test. The abscissa 
C D
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shows the different concentrations of CX-4945 used, on the ordinate the percentage of cells positive for annexin V
(apoptotic). The results shown are representative of 3 separate experiments (p <0.05)
D. The expression of total and cleaved PARP was determined by Western-blot analysis of protein lysates of NB4 cells, ML2 and
HL60 following treatment for 18 hours with increasing doses of CX-4945 and respective normalization with β-actin. 
CK2 inhibitors-induced apoptosis is p53-dependent
The refractoriness of HL60 cells to the CK2 blockade-induced apoptosis prompted us to test whether this
process was dependent on an intact p53 tumor suppressor function. In fact, HL60 are p53 null cells, due
to a gene deletion (51) and this suggested that the apoptosis consequent to CK2 inhibition could rely on
p53. To test this hypothesis we first analyzed p53 levels in wild-type p53 ML2 cells in different
conditions. After 6 hours of treatment with 5µM K27, p53 levels were investigated by WB and
densitometric analysis (Fig.4A ). K27-treated cells displayed a marked increase of p53 levels as compared
to vehicle-treated control cells. Since one major mechanism regulating p53 protein turnover is its
proteasome mediated degradation, as a control of our experiments we checked whether inhibition of the
proteasome could give the same p53 increased levels in AML cells. Indeed, treatment of ML2 cells with
10µM of proteasome inhibitor MG132 resulted in an accumulation of p53 in the cells (Fig.4A). This
result indicates that p53 expression and/or stability are likely regulated by CK2.
To further support our hypothesis that CK2 inhibition causes apoptosis through p53, we next made use of
another cellular model. We treated the p53-null human osteosarcoma cell line Saos-2 (52) with 10µM
K27 and analyzed cell viability by AV/PI staining and FACS analysis. We could confirm that also the
Saos-2 cells were resistant to CK2-inhibitors induced apoptosis. However, Saos-2 cells transfected with a
p53 wild-type expressing vector, but not Saos-2 cells transfected with an empty vector, displayed a
Figure 3: The pharmacological inhibition of
CK2 causes apoptosis in AML
Blasts isolated from 4 different patients with
AML and treated with the inhibitor of CK2α
K27 (black bars). As a control DMSO (white
bars), the medium in which K27 was dissolved,
was used. Apoptosis was analyzed by flow
cytometry using Annexin V staining. The
histograms show separately the results obtained
in 4 patients.
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significantly increased sensitivity to apoptosis induced by eighteen-hour treatment with 10µM
K27(p<0.05,n=3) These results were confirmed by experiments of gene silencing of CK2α by RNA 
interference in the same cell line (Fig. 4B). The cells were transfected with the plasmid vector p-CMV-
p53 or p-CMV control, selected on the basis of their neomycin resistance after a week of culture and
subsequently electroporated with an oligonucleotide inert (no target) or with an oligo-silencing for CK2α. 
After 72 hours, the analysis of apoptosis using Annexin V was made. The recovery of the expression of
p53 has, as expected, increased the percentage of apoptotic cells compared to the conditions in which it is
not expressed (cells not transfected or transfected with empty vector) (AV + 35.5% ± 0.7%), but
especially made the cells sensitive to apoptosis induced by silencing of CK2α (AV +43% ± 1.4) (Fig. 4C).
The total protein lysates were assayed by Western Blot analysis, which confirmed the silencing of CK2α 
and the presence of p53 in transfected cells. The levels of cleaved PARP were increased in cells in which
it has been restored the expression of p53 was restored and CK2α inhibited (Fig. 4D).
These results were next confirmed in HL60 cells transfected with the plasmid vector p-CMV-p53 or p-
CMV control, selected on the basis of their neomycin resistance after a week of culture and subsequently
treated with the inhibitor CX-4945 at 7 µM. After 18 hours of treatment the analysis of apoptosis by
Annexin V staining was assessed. As in Saos cells rescue of p53 expression sensitized HL60 cells to
apoptosis induced by CK2 inhibition . In particular , as expected, the recovery of the expression of p53
has increased the percentage of apoptotic cells compared to the conditions in which it is not expressed
(cells not transfected or transfected with empty vector) (AV + 61.1% ± 1.6%), but especially made the
cells sensitive to apoptosis induced by CK2 inhibitors (AV +67% ± 0.9%) ( Fig 4E and 4F).
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Figure 4: Expression of p53 protein and effect on the apoptosis induced by inhibition of CK2
A. Western-Blot analysis and relative densitometric values of the expression of p53 in total protein lysates of cells treated
or not with K27 ML2 5μM and MG132 (10μM) for 6 hours and relative normalization with β-actin. 
B. SAOS-2 transfected with an expression vector for p53; after 48 hours of transfection cells were subjected or not to
treatment with K27 (10μM) for 18 hours. The extent of apoptosis was assessed by the test of the AV. As a control cells 
A
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untransfected and transfected with a vector lacking an insert for p53 (pCMV) were used. The results are representative
of 3 separate experiments, p <0.05.
C. SAOS-2 cells transfected with an expression vector for p53 and subsequently transfected with an oligonucleotide short
interfering RNA to silence the gene of CK2α. The extent of apoptosis was assessed by the test of the AV. As a control 
cells untransfected and transfected with a vector lacking an insert for p53 (pCMV) in combination with an inert
oligonucleotide (oligo no target) were used. The results are representative of 2 separate experiments (* = p <0.05).
D. Western blot analysis of the expression of CK2α, p53, total and cleaved PARP, Caspase 3 total, phospho p65 and p65 
total, total protein lysates experiment silencing of Saos-2 and its normalization with β-actin. 
E. HL60 cells transfected with an expression vector for p53; after 48 hours of transfection cells were subjected or not to
treatment with Cx-4945 (7μM) for 18 hours. The extent of apoptosis was assessed by the test of the AV. As a control 
cells untransfected and transfected with a vector lacking an insert for p53 (pCMV) were used. The results are
representative of 3 separate experiments, p <0.05.
F. Morphological data before and after transfection and after treatment with CX-4945
AML cells show increased sensitivity to doxorubicin and daunorubicin after CK2 inhibition
Since in AML cells CK2 protein activity is increased as compared to normal CD34+ cells and its
inhibition sensitizes cells towards p53 partially-dependent apoptosis, we decided to investigate whether
hampering of CK2 activity rendered AML cells more susceptible to the cytotoxic effect of
chemoterapeutic drugs.
To this aim, ML2 cells were incubated for 18 hours with a combined treatment with subtoxic (4µM) K27
concentrations and increasing doses of daunorubicin (0.05-0.1-0.15 µM), an agent used in chemotherapy
protocols for the treatment of AML. AML cells were treated with the same concentrations of
daunorubicin and vehicle (DMSO 0.1%), as a control and analyzed with flow cytometry for the
expression of AV. A significant synergy of the chemotherapic agent and the inhibitor of CK2α in 
inducing apoptosis was found (AV + cells with K27 + dauno 0.05: 28.5% ± 1.7%; K27 + dauno 0.1: 29%
± 5.4, K27 + dauno 0.15: 35.75% ± 8.1%) (fig 5A) Also WB analysis of PARP cleavage confirmed the
cumulative effect of K27 and daunorubicin in inducing apoptosis (Fig5B). Next, treatment with
daunorubicin was combined with another CK2 inhibitor, the CX4945. ML2 cells were exposed for 18
hours to increasing doses of daunorubicin (0.05-0.1-0.15 µM) in the presence of a fixed dose of CX4945
4 µM. Cells were then analyzed by flow cytometry for the expression of AV. As for K27 treatment a
significant synergy between the chemotherapy agent and CX-4945 in inducing apoptosis was
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demonstrated (AV + cells with CX-4945 + dauno 0.05: 16.6% ± 1.5%; CX-4945 + dauno 0.1: 21,8% ±
5.0, CX-4945 + dauno 0.15: 23.5% ± 8 (Fig 5C and 5D).
Figure 5: Cytotoxic effect of combined treatment with daunorubicin and inhibitors of CK2
ML2 cells were treated for 18 hours with increasing doses of daunorubicin (0.05-0.1-0.15 mM) and with a constant dose of K27
(4 mM) (A) or CX-4945 (5 mM) (C). The apoptosis was assessed by staining with AV. treatments used are reported In the
abscissa with the respective concentrations, on the ordinate the percentage of annexin V-positive cells. The control consists of
untreated ML2 cells. The results shown for the combination of daunorubicin and K27 are representative of five separate
experiments, P <0.05, • p <0.05 compared to daunorubicin 0.05μM; # p <0.05 compared to daunorubicin 0.1μM; ♦ p <0.05 
compared to daunorubicin 12:15 μM. Results reported for the association of daunorubicin and CX are representative of four 
separate experiments, P <0.05, • p <0.05 compared to daunorubicin 0.05μM; # p <0.05 compared to daunorubicin 0.1μM; ♦ p 
<0.05 compared to daunorubicin 0.15μM. The expression of total and cleaved PARP was analyzed by Western Blot. The 
normalization was performed with β-actin (B) and GAPDH (D).
Lastly, the apoptotic response to the combined treatment was tested also on freshly isolated AML blasts
cultured onto a layer of HS-5 bone marrow stromal cells in order to mimic the patho-physiological
microenvironemt present in vivo. AML blasts were cultured in DMSO 0.1%, DMSO plus daunorubicin
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0.05 M, K27 3 M or both agents. AV staining and FACS analysis were then performed on cells
harvested from the co-cultures after 18 hours. By flow cytometric and western blot analysis (Fig. 6A and
6B) an increased apoptosis with the combination of the two agents was shown. Another series of
experiments on AML blasts patients was conducted using CX 4945 5 M combined with daunorubicin, as
shown in Fig 6C and 6D.
Figure 6: Effect of anthracycline and CK2 inhibitors in cells of acute myeloid leukemia
Blasts isolated from a patient with AML and treated for 18 hours with increasing concentrations of daunorubicin (0,5-1 mM) and
K27 (3 uM) above (A-B) or with CX-4945 (5 uM) below (C-D). The extent of apoptosis was assessed by an assay of AV and
WB.
CK 2 silencing by RNA interference causes apoptosis and empowers daunorubicin-dependent
citotoxicity in AML cells
To further analyze the role of CK2 in AML cell survival and resistance to apoptosis we performed RNA
interference experiments to knock down CK2 protein expression levels in ML2 cells. ML2 cells were
transfected with oligonucleotides directed against the α catalytic subunit, the regulatory subunit β or a 
combination of both. As control cells transfected with oligonucleotides lacking specific target (no target)
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were used. The efficiency of transfections was verified by parallel electroporations of inert
oligonucleotides marked with green fluorophore (siglo green). Silencing of both CK2 subunits was
confirmed respectively by real-time PCR (Figure 7A) and by Western blot analysis. The efficiency of
transfection was high (transfected cells ranged from 80% to > 90%) in all the experiments performed (not
shown). As shown in Figure 7B we could achieve a significant reduction of CK2  and CK2  expression
at both mRNA and protein levels, peaking 48 hours and lasting as long as 72 hours. Knock down of CK2
 and CK2  was associated to a significant increase in apoptosis as shown by AV staining and PARP
cleavage (Figure 7b and 7c), along the same line of CK2 chemical inhibition experiments.
48 hours after transfection ML2 cells were treated with two different doses of daunorubicin (0.15 uM and
0.25 uM) for additional 18 hours and then evaluated for apoptotic response by PARP cleavage and AV
staining analysis (Fig. 7B and 7C). Interestingly, the protein expression of CK2 β may be reduced in the 
presence of down-modulation of single catalytic subunit α (1.37 for the β subunit, 1.07 for the α subunit, 
normalized data on the value of the control transfected with no oligonucleotide target after densitometric
analysis). The apoptotic cells, however, further increase after association with daunorubicin, giving
statistically significant results in the presence of down-regulation of both subunits and treatment with the
lower dose of chemotherapeutic (0.15 uM) (siRNA CK2β + daunorubicin 0.15μM: 1.98, siRNA CK2β + 
daunorubicin 0.25μM: 2.38, CK2α siRNA + daunorubicin 0.15μM: 1.38, CK2α siRNA + daunorubicin 
0.25μM: 2.07; siRNA CK2α and CK2β + daunorubicin 0.15μM: 1.93, CK2α and CK2β siRNA + 
daunorubicin 0.25μM: 2.75: normalized data on value of the control transfected with no target 
oligonucleotide in the absence of daunorubicin, after densitometric analysis) (Fig. 7C).In fact the Western
blot analysis shows an increase of the sensitivity of the cells to daunorubicin: it an increase of the
cleavage of PARP at the lowest dose of the chemotherapeutic agent was observed when the single β 
subunit or both β and α were silenced (Fig. 7B)
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Figure 7: Response of the line ML2 to treatment with daunorubicin following the silencing of CK2
A. Expression of CK2α and CK2β determined by real-time PCR performed on cDNA ML2 cells transfected with 
oligonucleotides directed against the mRNA of the β subunit and α of CK2 (CK2β siRNA and siRNA CK2α respectively). 
The control is represented by cells transfected with oligonucleotides without target (no target oligo). The results were
obtained from 4 independent experiments, P <0.05.
B. Protein levels at 72 hours of CK2α, CK2β and cleaved PARP and total lysates of total protein of the cell line ML2, treated 
with daunorubicin (0.15 uM and 0.25 uM) after silencing by RNA interference (siRNA) of the subunits α and β. Below 
normalization with GAPDH.
C. Percentage of apoptosis (normalized data compared to untreated control) of ML2 cells after transfection with siRNA CK2α, 
CK2β siRNA and siRNA CK2α + CK2β and treatment with daunorubicin (0.15 uM, 0.25 uM). The abscissa shows the 
combinations of different treatments. The results obtained are representative of 4 independent experiments. p <0.05 * p <0.05
CK2 subcellular localization is modulated by doxorubicin in AML cells
Since inhibition of CK2 renders AML cells more susceptible to doxorubicin-induced cell death, we next
sought to determine whether there could be a cross-talk between doxorubicin-induced pathways and CK2.
To this aim, we analyzed CK2α expression levels and kinase activity in ML2 cells exposed for 6 hours to 
doxorubicin at increasing concentrations (0.4-0.8µM). CK2 α protein expression levels were found 
slightly increased after 6 hours upon doxorubicin treatment. Also CK2 kinase activity increased after
doxorubicin treatment (data not shown). We analyzed CK2α cellular distribution upon doxorubicin 
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treatment in AML cells. IF microscopy experiments of AML cells exposed to 0.8µM doxorubicin for as
long as 6 hours revealed that CK2α redistributed from cytoplasm into the nuclear compartment (Fig. 8A).
This result was confirmed in WB experiments, in which CK2α protein expression was investigated in the 
cytoplasmic and nuclear cellular protein fractions: while in untreated AML cells CK2α was 
predominantly present in the cytoplasmic fraction, after doxorubicin treatment for 6 hours it was
detectable mostly in the nuclear fraction (Fig. 8B). Thus, CK2α changes its intracellular localization upon 
exposure to a chemotherapeutic drug in AML cells.
A B
The combination of CK2 inhibitors and daunorubicin induces apoptosis of AML cells with a
synergic effect
The observation that the cytotoxic effect of daunorubicin is enhanced by CK2 blockade prompted us to
further investigate the basis of this cooperation using the Combination Index (CI). ML2 cells were treated
with sequential doses of K27, CX 4945 and daunorubicin, after 18 hour. After 48 hours the rate of cell
proliferation was assessed by tritiated thymidine proliferation assay (counts per minute). First, for each
drug was determined the IC 50 (concentration of the drug that is required for 50% inhibition in vitro):
IC50 daunorubicin = 0.0188 μM; IC50 CX-945 = 16.65925 μM; IC50 K27 = 5.7 μM ant then was
Figure 8: Relocalization of CK2α following treatment with CK2α.
A. Immunofluorescence performed on cells ML2. CK2α is red, the nucleus is blue
(DAPI). In the upper box untreated cells are shown, in the box below cells treated
with doxorubicin (0.8μM) for 6 hours.
B. The expression of CK2α was evaluated by Western-blot analysis of cytoplasmic
and nuclear protein lysates of cells ML2 treated for 6 hours with doxorubicin (0.4
and 0.8μM); densitometric values normalized on the -actin are shown.
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determined the IC50 for the combination of the two drugs. The concentrations obtained for each
combination were lower than the IC50 obtained in the single treatment (daunorubicin IC50 after
combination with CX-4945: 0.008 M; IC50 CX-4945 after combination with daunorubicin: 7.48911 M;
daunorubicin IC50 after combination with K27: 0.0058 M; IC50 K27 after combination with
daunorubicin: 2.28uM).
It was then possible to relate the different IC50 values acquired for each pair of treatment, obtaining for
both associations a Combination Index less than 1 (CI daunorubicin + CX-4945: 0.86; CI daunorubicin +
K27: 0.7). A synergistic proapoptotic effect of the combined treatment of daunorubicin with both
inhibitors of CK2 could be demonstrated (Fig. 9).
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Fig 9: Combination Index of the combination daunorubicin/CK2 inhibitors CX-4945 or K27
The cell proliferation and therefore the incorporation of tritiated thymidine incorporation is expressed as counts per minute
(CPM), reported on the ordinate. The concentrations of the different agents used are reported in abscissa. The results are
representative of 3 independent experiments after 48 hours of treatment.
A. Dose-response curve with IC50 values of daunorubicin alone or in combination with CX (left) and the corresponding curve
after treatment with IC50 values of CX alone or combined with daunorubicin (right)
B. Dose-response curve with IC50 values of daunorubicin alone or in combination with K27 (left) and of IC50 values of K27
alone or in combination with daunorubicin (right).
CK2 modulates daunorubicin-induced activation of JAK-STAT pathway
To unravel molecular mechanisms underlying the synergistic proapoptotic effect of daunorubicin and
CK2 blockade we focused on signalling pathways modulated by doxorubicin, genotoxic stress and CK2.
Among many signalling cascades, we first look at the JAK-STAT pathway, a critical mediator of the
DNA damage response (DDR ) and doxorubicin resistance (53). In fact, very recent studies have shown
that it is activated by CK2 (47).
ML2 cells were treated with K27 4 μM or CX-4945 5 μM plus different concentrations of daunorubicin 
(0.05 μM, 0.1 μM, 0.15 μM). 
We evaluated the activation of JAK/STAT pathway after 18 hours by assessing expression levels of two
target genes of STAT such as mcl-1, anti-apoptotic gene, and SOCS3, suppressor of JAK receptor by RT-
PCR and Western Blot analysis (Fig. 10). The state of phosphorylation in serine 727 of STAT3, active
form of the transcription factor, was also investigated. As expected STAT3 was found to be constitutively
phosphorylated in ML2 cells. The treatment with daunorubicin induced a slight increase of
phosphorylated STAT3 and STAT3-dependent transcription, as shown by increased expression of mcl-1
and SOCS3.
Then association of the daunorubicin treatment was combined with the CK2 inhibitors: the block of the
pathway activation yet at daunorubicin subtoxic dose (0.05 mM) was demonstrated by the reduction of
phosphorylated STAT3 and reduced levels of mcl-1 and SOCS3 (Fig. 10).
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Figure 10: Analysis of the state of activation of the JAK/STAT pathway after treatment with daunorubicin in
the presence or absence of K27 or CX-4945
A. Western Blot analysis after treatment with daunorubicin and K27 (on the left) or CX-4945 (on the right). Normalization with
GAPDH.
B-C. Real-time PCR for genes mcl-1 (on the top) and SOCS3 (on the bottom) following treatment with daunorubicin and CX-
4945 (on the left) or daunorubicin and K27 (on the right). The ordinate shows the levels of expression normalized on the
untreated control (NT) and the abscissa the different treatments used. The data obtained are derived from three different
independent experiments. * p <0.05, • p <0.05 compared to daunorubicin 0,05 uM
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CK2 α and β expression analysis of in primary AML cells
In order to translate our in vitro studies into a clinical setting, CK2 espression levels were then
sistematically assessed in AML primary cells. Patients were divided into two groups (CK2α-high versus 
CK2α-low) according to the levels of constitutive expression of CK2α protein in pretreatment AML 
samples as described in the statistical analysis (ratio CK2 absorbance/GAPDH absorbance > or < 0,75).
Western blot analysis revealed that the expression of CK2α protein was elevated in 17 out of the 27 AML 
samples. Considering the ELN prognostic classification a high expression was found: in 2 (29%) of the 7
patients with a favorable risk class, in 8 (61%) of the 13 patients with an INT-1 risk class,4 (100%) of the
4 patients with an INT-2 risk class and 2 (100%) of the 2 patients with a high risk class. Representative
Western blot analysis is shown in Fig. 11.
Fig.11: Representative Western Blot Analysis of expression of CK2α and CKβ in AML patients classified on the basis of 
ELN prognostic classification.
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While high CK2α expression levels associated with highest risk classes, interestingly AML samples 
belonging to INT-1 risk class showed a bimodal expression profile (Fig.12).
Fig 12: CK2α expression (densitometric values) of 27 patients with AML. Patients are divided in the 4 prognostic ELN 
groups.
The same arbitrary cut off was adopted for the β subunit. Western blot analysis revealed that the 
constitutive expression of CK2β protein was high in 21 out of the 27 patients evalauted for the expression 
of this subunit. Considering the ELN prognostic classification a high CK2β expression was found: in 6 
(86%) out of the 7 patients with a favorable risk class ; in 8 (61%) out of the 13 patients with an INT-1
risk class; 3 (60%) out of the 5 patients with an INT-2 risk class and 4 (80%) out of the 5 patients with a
high risk class. Representative Western blot analyses are shown in Fig.13.
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Fig 13: CK2β expression (densitometric values) of 32 patients with AML. Patients are divided in the 4 prognostic ELN 
groups.
Prognostic significance of CK2α expression in AML
The association of CK2α expression with various clinical variables was then evaluated. There was no 
significant difference in the patient age and sex in relation to CK2α expression. Kaplan-Meier survival 
curves showed that overall survival rate was lower in CK2α-high AML compared with the CK2α-low 
AML cases, though it did not reach statistical significance given the low number of samples analyzed
(Fig 14). Along the same line Kaplan-Meier survival curves in the group of patients who underwent
chemotherapy showed a better outcome, yet not statistical significant as above, in patients displaying low
expression of CK2 α (Fig 15). Kaplan Meier survival analysis showed that there was not difference on
overall survival depending on the CK2β levels (data not shown). 
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Fig. 14.: Kaplan Meier survival curves in Ck2 α high 
risk AML compared with the CK2α-low AML (p=0.2)
Fig 15.: Kaplan Meier survival curves in Ck2α high risk 
AML compared with the CK2α-low AML (p=0.1) in 
patients who underwent chemotherapy
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DISCUSSION
Acute myeloid leukemia is the most common acute leukemia diagnosed in adults patients. Although most
patients achieve complete remission with induction chemotherapy, the majority of patients relapse after
achieving clinical remission.
The use of consolidation therapy with high dose cytarabine or stem cells transplantation has improved
outcomes in adult AML patients; however despite the use of intensive consolidation strategies outcomes
for AML patients remain poor. Nowadays the most important prognostic factors to predict response to
chemotherapy is the cytogenetic profile together with molecular markers such as NPM1 and FLT3. As
recently proposed and validated by the European Leukemia Network (23), AML patients can be stratified
into different prognostic risk groups according to their chromosomal abnormalities. However, 45% of
adults with de novo AML have normal karyotype and therefore lack chromosomal markers. This
heterogeneous cohort of patients has variable clinical outcomes. Given that intensive treatments, such as
allogeneic hematopoietic stem cell transplantation, are associated with high treatment-related mortality,
the elucidation of novel prognostic markers can lead to the development of risk-adapted therapeutic
strategies in karyotypically normal AML patients. We have shown here that CK2 is highly expressed in
AML cells, regulates AML cell survival and sensitivity to doxorubicin and daunorubicin by modulation
of the Jak-Stat signaling pathway.
CK2 is emerging as a critical cellular serine-threonine kinase that regulates a large array of processes
related to cell survival and proliferation (31). The role of CK2 in sustaining cell growth is markedly
exploited by malignant cells that seemingly rely on CK2 activity in a “non-oncogene addicted” fashion to
keep oncogenic pathways constitutively activated (48). Most of the AML cell lines used in this study
displayed increased levels and activity of CK2. Our data confirmed that CK2 upregulation accompanies
the transformed phenotype in malignant hematopoietic cells and are consistent with what has been found
in several types of solid tumor cell lines and tissues. Remarkably, the cytotoxic effect of the CK2
inhibitors was also evident in freshly isolated AML blasts from patients. Thus, the efficacy of inducing
AML cell apoptosis by the CK2 inhibitors is similar both in AML cell lines and primary AML cells.
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Compelling evidence was also provided that CK2 inhibition at least in part leads to AML apoptosis in a
p53-dependent fashion. In fact, the p53-mutated HL60 AML, as well as Saos osteosarcoma cell lines,
displayed refractoriness to the cytotoxic effect triggered by CK2 inhibitors K27 and CX 4945. Most
importantly, restoring a normal p53 function in HL60 and Saos cells was associated with the acquisition
of sensitivity to CK2 inhibitors and rendered these cells prone to apoptosis induced by these compounds.
The molecular relationships between CK2 and p53 are complex and not fully understood. CK2 can
phosphorylate p53 in S392 upon UV light exposure and this would increase p53 transcriptional activity
(54,55). However, in in vivo mouse models CK2 over-expression synergized with p53 loss in inducing
lymphomas (56). Other studies also provided evidence that CK2 antagonizes p53 tumor suppressor
activity [reviewed in (28). The results obtained in our study suggest that AML in which p53 function is
lost are resistant to CK2 inhibition-induced cell death and might not present CK2 overexpression or
increased function. Indeed, HL60 did not display these features (Fig. 1D, E), while the most CK2-
inhibition sensitive AML cell lines, NB4 and ML2, did. We also demonstrated that in p53 wild-type
expressing AML cells, CK2 inhibition was accompanied to an accumulation of p53, suggesting that CK2
activity would be important for the regulation of p53 protein turnover in AML cells.
Most importantly, we established that the anti-apoptotic role of CK2 in AML cells is pivotal in protecting
AML cells against drug-induced apoptosis. We have shown that doxorubicin and daunorubicin, a widely
used drugs for the therapy of both solid tumors and hematological malignancies, induces AML cell
apoptosis at a higher rate in the abscence of CK2 function, suggesting that CK2 regulates anti-apoptotic
signaling pathways involved in doxorubicin and daunorubicin-incuced cell death (Fig.4A, B). The
protective effect of CK2 against doxorubicin was also evident both in AML cell lines and in AML blasts
freshly isolated and grown onto a layer of stromal cells (Fig. 4C, D). This latter effect suggests that the
cooperation between the chemotherapic agents and the CK2 inhibitor is effective also when mimicking
the AML malignant microenvironment. To note, we demonstrated that doxorubicin triggers the nuclear
shift of CK2, without significant changes in its protein levels and kinase activity. CK2 nuclear functions
are largely unknown, however, it is believed that in the nucleus CK2 might influence the activity of
transcription factors and of the DNA-damage molecular machineries, thus regulating cell life fate (28). In
this regard, we demonstrated that one of the major anti-apoptotic cascade elicited by the exposure of
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tumor cells to chemotherapeutics, the Jak Stat pathway, is strongly activated by daunorubicin in AML
cells. The use of the CK2 inhibitors concomitant to the chemotherapy is able to reduce this activation as
demostrated by the reduction of Stat phosphorylation as well as of Mcl-1 and Socs3 transcription. The
prognostic role of CK2a in AML has been so far explored only by single study (57) focused only patients
with normal karyotype without stratification into the cytogenetic risk groups. In our study we analyzed
CK2 in representative samples from the different AML cytogenetic risk groups and demonstrated that
CK2high expression levels associate with higher risk groups. Moreover, INT1 risk group could be
stratified in two subgroups based on CK2high and -low expression levels suggesting that CK2 may
play a role as prognostic factor together with well-known molecular markers such as FLT3 and NPM.
Survival analysis resulted statistically not significant because of the low number of samples analyzed.
However being overall survival rate lower in CK2α-high AML compared to the CK2α-low AML cases, 
especially in patients treated with chemotherapy, this pattern suggests a prognostic significance of CK2
expression. On the other hand, Ck2 expression resulted to be extremely variable and not related to
different prognostic groups
In summary, this study provides experimental evidence that AML cell survival relies at least in part on an
intact CK2 function. CK2 might protect against chemotherapy-induced cell death through inhibition of
p53 and activation of Jak-Stat. Therefore, the pharmacological disruption of CK2 could achieve the goal
of restoring p53 function while simultaneously inhibiting Jak-Stat activity and could be envisioned as a
complementary therapeutic strategy in the management of p53 wild-type/Stat overexpressing AML.
Moreover our study suggests a role for CK2α expression as prognostic marker in AML further 
contributing to the class risk profiling.
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